Stem Cells for Cardiovascular Disease 2009 Market Report

Summary

This is the latest and most up-to-date Worldwide Stem Cells Market Report from Select Biosciences, based on our continual industry coverage. Select Biosciences industry coverage in this report focuses on the technical, market, and clinical trials aspects of stem cells being developed for addressing the opportunities in the cardio and vascular disease spaces. Major emphasis is placed on the various clinical applications of mesenchymal stem cells (MSCs)-a key stem cell lineage of paramount importance for regenerative medicine. A Major Focus of this Report is on the Market Landscape and Quantitative Market Trends in Cardiovascular Disease utilizing various types of stem cell classes/lineages. Another key focus of this report is on the various clinical trials either completed or in progress addressing different therapeutic areas across the cardiovascular diseases landscape.

Extensive Worldwide Market Analyses Presented in this Report:

• Results and Analyses from Stem Cells-Focused Market Surveys Administered to Large Respondent Pools of Industry Participants focused on Stem Cells-Qualitative and Quantitative Market Trends are Analyzed and Presented focusing on the cardiovascular disease spaces
• Breakout of the Market by Types of Stem Cells Utilized and Application Areas-in various therapeutic segments of the cardiovascular disease therapeutics marketplace
• Quantitative Breakout of various types of stem cells in research and clinical development for cardiovascular diseases
• Breakout of the Market by Therapeutic/Disease Segments Addressed-in the various segments of the cardiovascular disease space
• Worldwide Stem Cells-focused Clinical Trials for Cardiovascular Diseases
• Qualitative and Quantitative Trends
• Sponsoring Institutions/Companies
• Types of Trials
• Types of Cells Utilized
• Clinical End-Points
• Progress Reports
• Competitive Landscape: Companies Focused on Developing Stem Cells-focused Cellular Therapies for Different Disease Areas in the Cardiovascular Space-Qualitative and Quantitative Analyses
• Impact of Mesenchymal Stem Cells (MSCs) and other stem/progenitor cell types for mediating cardiovascular disease regenerative medicine
• Mechanisms of action of MSCs in cardiovascular disease regenerative medicine
• Delivery approaches for cellular therapy of cardiovascular diseases

Companies Profiled in This Market Report:

• Aastrom Biosciences
• Aldagen
• Angioblast Systems
• Arteriocyte
• Athersys
• Bioheart
• Cytori
• Geron
• Medistem
• Mytogen
• Osiris Therapeutics
• Pluristem
• t2cure
• TheraVitae

Contents

• Chapter I. Executive Overview of the Space
  • Scope of this Market Report
  • Challenges in the Cellular Therapy Space
  • Cardiovascular Disease Market Segmentation
  • Cardiovascular Disease Market Opportunity
  • Embryonic Stem Cell (ESC) Differentiation into Multiple Cellular Lineages
• Chapter II. Mesenchymal Stem Cells (MSCs) for Regenerative
  • Medicine
  • MSCs: Definition and Properties
  • MSC Phenotype
  • Heart Cell Lineage Diversification
  • Pericytes: Tissue-Specific Progenitors
  • Mechanisms of MSC-mediated Tissue Repair
  • Fetal versus Adult MSCs
• Chapter III. Stem Cells for Cardiovascular Disease: Technology
  • Landscape, Market Landscape, Clinical Trials Landscape
  • Cellular Therapy for Cardiovascular Diseases
  • Proposed Mechanisms of MSC-mediated Cardiovascular Repair
  • Potential Delivery Routes of MSC-based Cellular Therapy for
  • Cardiovascular Diseases
  • Safety Concerns with Stem Cell Therapy for Cardiovascular Disease
  • Quantitative Market Analysis of the Cardiovascular Regenerative
  • Medicine Space
  • Stem Cells for Cardiovascular Disease: Clinical Trials Landscape
• Chapter IV. Stem Cells for Cardiovascular Disease: Selected Industry Events and Companies in the Space
  • Selected Industry Events in Cardiovascular Cellular Therapy Space
  • Profiles of Companies in the Cardiovascular Cellular Therapy Space
• Appendix I. Research Methodology Appendix II. Stem Cells for Cardiovascular Disease: Worldwide Clinical Trials Details
• Appendix III. Cardiovascular Disease Patient Population Statistics